U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H24N4O3
Molecular Weight 404.4625
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OZANIMOD

SMILES

CC(C)Oc1ccc(cc1C#N)-c2nc(-c3cccc4c3CC[C@]4([H])NCCO)no2

InChI

InChIKey=XRVDGNKRPOAQTN-FQEVSTJZSA-N
InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H24N4O3
Molecular Weight 404.4625
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Ozanimod (previously known as RPC-1063) is a selective immune-inflammatory modulator of the G protein-coupled receptors sphingosine 1-phosphate 1 and 5, which are part of the sphingosine 1-phosphate (S1P) receptor family. Treatment with S1P receptor modulators interferes with S1P signaling and blocks the response of lymphocytes (a type of white blood cell) to exit signals from the lymph nodes, sequestering them within the nodes. The result is a downward modulation of circulating lymphocytes and anti-inflammatory activity by inhibiting cell migration to sites of inflammation. Ozanimod is currently in phase III clinical trials for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis, and also in phase II clinical trials to determine whether it is effective in the treatment of Crohn's disease.

CNS Activity

Curator's Comment:: effectively crossing the blood–brain barrier resulting in exposure in the brain

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P21453
Gene ID: 1901.0
Gene Symbol: S1PR1
Target Organism: Homo sapiens (Human)
0.41 nM [EC50]
Target ID: Q9H228
Gene ID: 53637.0
Gene Symbol: S1PR5
Target Organism: Homo sapiens (Human)
11.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.409 ng/mL
1.5 mg 1 times / day steady-state, oral
dose: 1.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OZANIMOD plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7.66 ng × h/mL
1.5 mg 1 times / day steady-state, oral
dose: 1.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OZANIMOD plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
21.4 h
1.5 mg 1 times / day steady-state, oral
dose: 1.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OZANIMOD plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Other AEs: Nasopharyngitis, Headache...
Other AEs:
Nasopharyngitis (9.7%)
Headache (6%)
Upper respiratory tract infection (6.8%)
Alanine aminotransferase increased (2.6%)
Back pain (2.2%)
Gamma-glutamyltransferase increased (2.2%)
Respiratory tract infection viral (2.2%)
Urinary tract infection (1.8%)
Hypercholesterolaemia (1.3%)
Hypertension (2.4%)
Pharyngitis (1.3%)
Rhinitis (1.8%)
Upper abdominal pain (2%)
Sources: Page: 9
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Other AEs: Nasopharyngitis, Headache...
Other AEs:
Nasopharyngitis (6.7%)
Headache (7.6%)
Upper respiratory tract infection (4%)
Alanine aminotransferase increased (4.7%)
Back pain (3.8%)
Gamma-glutamyltransferase increased (3.3%)
Respiratory tract infection viral (3.3%)
Urinary tract infection (3.8%)
Hypercholesterolaemia (2.5%)
Hypertension (1.3%)
Pharyngitis (2.5%)
Rhinitis (2%)
Upper abdominal pain (1.3%)
Sources: Page: 9
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Other AEs: Upper respiratory infection, Transaminases increased...
Other AEs:
Upper respiratory infection (26%)
Transaminases increased (10%)
Orthostatic hypotension (4%)
Urinary tract infection (4%)
Back pain (4%)
Hypertension (4%)
Abdominal pain upper (2%)
Sources: Page: 8
0.92 mg 1 times / day multiple, oral
Recommended
Dose: 0.92 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.92 mg, 1 times / day
Sources: Page: 6
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 6
Disc. AE: Hepatic enzymes increased...
AEs leading to
discontinuation/dose reduction:
Hepatic enzymes increased (1%)
Sources: Page: 6
AEs

AEs

AESignificanceDosePopulation
Hypercholesterolaemia 1.3%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Pharyngitis 1.3%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Rhinitis 1.8%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Urinary tract infection 1.8%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Upper abdominal pain 2%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Back pain 2.2%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Gamma-glutamyltransferase increased 2.2%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Respiratory tract infection viral 2.2%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Hypertension 2.4%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Alanine aminotransferase increased 2.6%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Headache 6%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Upper respiratory tract infection 6.8%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Nasopharyngitis 9.7%
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 467
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 467
Sources: Page: 9
Hypertension 1.3%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Upper abdominal pain 1.3%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Rhinitis 2%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Hypercholesterolaemia 2.5%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Pharyngitis 2.5%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Gamma-glutamyltransferase increased 3.3%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Respiratory tract infection viral 3.3%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Back pain 3.8%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Urinary tract infection 3.8%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Upper respiratory tract infection 4%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Alanine aminotransferase increased 4.7%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Nasopharyngitis 6.7%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Headache 7.6%
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources: Page: 9
unhealthy, 18 - 55 years
n = 448
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 18 - 55 years
Sex: M+F
Population Size: 448
Sources: Page: 9
Transaminases increased 10%
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Abdominal pain upper 2%
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Upper respiratory infection 26%
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Back pain 4%
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Hypertension 4%
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Orthostatic hypotension 4%
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Urinary tract infection 4%
0.84 mg 1 times / day multiple, oral
Recommended
Dose: 0.84 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.84 mg, 1 times / day
Sources: Page: 8
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 8
Hepatic enzymes increased 1%
Disc. AE
0.92 mg 1 times / day multiple, oral
Recommended
Dose: 0.92 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.92 mg, 1 times / day
Sources: Page: 6
unhealthy, mean age 35.4 years
n = 882
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: mean age 35.4 years
Sex: M+F
Population Size: 882
Sources: Page: 6
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes [IC50 22.8 uM]
unlikely
Comment: At clinically relevant concentrations of CC112273 and CC1084037, inhibition of BCRP is not expected
Page: 17.0
yes [IC50 25.2 uM]
unlikely
Comment: At clinically relevant concentrations of CC112273 and CC1084037, inhibition of BCRP is not expected
Page: 17.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
major
major
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: Co-administration of gemfibrozil (a strong inhibitor of CYP2C8) 600 mg twice daily at steady state and a single dose of ozanimod 0.46 mg resulted in no clinically meaningful changes in exposure (AUC) of ozanimod and increased exposure (AUC) of active metabolites CC112273 and CC1084037 by approximately 47% and 69%, respectively
Page: 31.0
yes
yes (co-administration study)
Comment: Coadministration of itraconazole (a strong inhibitor of CYP3A4) twice daily at steady state and a single dose of ozanimod 0.46 mg had no significant effect on ozanimod Cmax and AUCinf. Itraconazole decreased the Cmax of the major metabolites CC112273 and approximately 21% and 22%, respectivelyCC1084037 by
Page: 11.0
Tox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
2016 Jun
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
2016 May 5
Patents

Patents

Sample Use Guides

Multiple Sclerosis: 1 mg RPC1063 (Ozanimod) oral capsule daily
Route of Administration: Oral
Ozanimod (RPC1063) is a specific agonist for sphingosine-1-phosphate receptor subtypes 1 (S1P1) and S1P5 receptors. The EC50 values were 0.16 nM and 0.41 nM for S1P1 receptors in the inhibition of cAMP generation and [35S]-GTPγS binding. The 83% Emax value of ozanimod against S1P5 receptor was 11 nM. RPC1063 demonstrated a dose‐dependent effect on S1P1 receptor re‐expression on the cell surface, with near complete and sustained loss of cell surface receptor expression at concentrations above 10 nM in S1P1 receptor-HEK293T cells after 1 h incubation.
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:57:50 UTC 2021
Edited
by admin
on Fri Jun 25 23:57:50 UTC 2021
Record UNII
Z80293URPV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OZANIMOD
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
OZANIMOD [WHO-DD]
Common Name English
RPC-1063
Code English
BENZONITRILE, 5-(3-((1S)-2,3-DIHYDRO-1-((2-HYDROXYETHYL)AMINO)-1H-INDEN-4-YL)-1,2,4-OXADIAZOL-5-YL)-2-(1-METHYLETHOXY)-
Systematic Name English
OZANIMOD [USAN]
Common Name English
OZANIMOD [INN]
Common Name English
RPC1063
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 499515
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
WHO-ATC L04AA38
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
FDA ORPHAN DRUG 611517
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
Code System Code Type Description
DRUG CENTRAL
5383
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
DRUG BANK
DB12612
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
NCI_THESAURUS
C170279
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
LACTMED
Ozanimod
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
FDA UNII
Z80293URPV
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
PUBCHEM
52938427
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
INN
10057
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
EVMPD
SUB181335
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
CAS
1306760-87-1
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
RXCUI
2288236
Created by admin on Fri Jun 25 23:57:50 UTC 2021 , Edited by admin on Fri Jun 25 23:57:50 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SELECTIVE
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
Ozanimod was not present in feces. Ozanimod concentration in urine was negligible.
FECAL; URINE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
TARGET -> AGONIST
SELECTIVE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
FECAL
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE INACTIVE -> PARENT
MAJOR
FECAL
METABOLITE ACTIVE -> PARENT
PLASMA; URINE
METABOLITE INACTIVE -> PARENT
FECAL; PLASMA; URINE
METABOLITE INACTIVE -> PARENT
MAJOR
FECAL
METABOLITE ACTIVE -> PARENT
PLASMA
METABOLITE -> PARENT
FECAL
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC AT STEADY-STATE